Literature DB >> 1985732

A dose-intensive regimen of 5-fluorouracil for the treatment of metastatic colorectal carcinoma.

E A Poplin1, M Kraut, L Baker, J Brodfuehrer, V Vaitkevicius.   

Abstract

5-Fluorouracil (5-FU) was delivered in a dose-intensive schedule to 23 patients with metastatic or unresectable colorectal carcinoma. The schedule consisted of bolus single-dose 5-FU therapy 400 to 500 mg followed by 4-day infusion of 5-FU, 600 to 800 mg/m2/day, followed by a 17-day to 24-day infusion of 200 to 250 mg/m2/day. Partial remissions were seen in 22% of all eligible patients. Significant toxicity, including mucositis, diarrhea, and hand-foot syndrome, necessitated dose reductions in most patients. The authors conclude that 5-FU given in this moderately intensive schedule is associated with a moderate level of response, as easily achieved with more conventional schedules or with 5-FU-leucovorin combinations. Tumor responsiveness to dose intensive 5-FU regimens may be limited.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1985732     DOI: 10.1002/1097-0142(19910115)67:2<367::aid-cncr2820670209>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  Suppressive effect of doxorubicin on liver recurrence after resection of colonic VX2 cancer lesions: difference in efficacy according to the injection protocol.

Authors:  M Sakane; Y Tabuchi; Y Saitoh
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

2.  Continuous infusion of 5-fluorouracil with alpha 2b interferon for advanced colorectal carcinoma.

Authors:  J E Ferguson; P Hulse; P Lorigan; G Jayson; J H Scarffe
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.